Paul G. Richardson, MD

Paul G. Richardson, MD, discusses what is expected and exciting for the future of multiple myeloma research.

Paul G. Richardson, MD, discusses the unmet medical needs that still exist in the multiple myeloma space.

Paul G Richardson, MD, discusses the ways treatment approaches for patients with multiple myeloma has changed over the past few years.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

Paul G. Richardson, MD, discusses the response rates observed in the first-in-human phase 1 trial of CC-92480 and dexamethasone in patients with relapsed/refractory multiple myeloma.

Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.

Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses results from the phase III OPTIMISMM trial comparing treatment regimens for relapsed/refractory multiple myeloma. This data compares a regimen of pomalidomide, bortezomib, and dexamethasone versus bortezomib and dexamethasone alone.